Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024 - Seite 2

Presenters: Elizabeth Abelovski and Nicholas Dedeic
Date and Time: Monday, April 8, 2024, 9:00 AM-12:30 PM PT
Key Highlights:

• CD73 is a cell surface enzyme responsible for the production of adenosine, which is immunosuppressive and leads to immune evasion in solid tumors
• Adenosine production can be inhibited therapeutically by enzyme inhibition and receptor internalization and subsequent degradation
• In human triple-negative breast cancer cell lines, CBO421 demonstrated potent and complete CD73 enzyme inhibition and robust CD73 receptor internalization in CD73 cancer cells, superior to oleclumab, an anti-CD73 monoclonal antibody
  

Abstract Title: CBO421: A novel drug Fc-conjugate to prevent tumor immune evasion via the CD73/adenosine pathway
Presenters: Amanda Almaguer and Doug Zuill
Date and Time: Monday, April 8, 2024, 1:30-5:00 PM PT
Key Highlights:

• CBO421 demonstrated strong binding affinity and potent inhibition of both soluble and membrane bound CD73, differentiating it from monoclonal antibody CD73 inhibitors
• The candidate also exhibited high potency in functional cell-based assays and robust antitumor efficacy in a syngeneic mouse model

Abstract Title: CCR5-001, a novel Drug Fc-Conjugate (DFC) targeting CCR5, demonstrates potent efficacy in a colorectal cancer mouse model
Presenter: Simon Döhrmann, Ph.D.
Date and Time: Monday, April 8, 2024, 1:30-5:00 PM PT
Key Highlights:

• CCR5 is expressed on multiple immune cells and can contribute to an immune-suppressive tumor microenvironment, limiting response to immune checkpoint inhibitors
• First-in-class CCR5-targeting DFC, CCR5-001, demonstrated potent CCR5 binding and functional inhibition of CCR5 signaling in cell-based assays
• The candidate also demonstrated robust efficacy as a monotherapy in a syngeneic colorectal cancer mouse model, representing a potential to target CCR5 with DFCs in solid cancers where pathology is driven by the CCR5/CCL5 axis
  

About Cidara Therapeutics
Cidara Therapeutics is using its proprietary Cloudbreak platform to develop novel drug-Fc conjugates (DFCs). These targeted immunotherapies offer the unique opportunity to create “single molecule cocktails” comprised of targeted small molecules and peptides coupled to a human antibody fragment (Fc). DFCs are designed to save lives and improve the standard of care for patients facing cancers and other serious diseases by inhibiting specific disease targets while simultaneously engaging the immune system. In addition, Cidara received FDA approval for REZZAYO (rezafungin for injection), which it has licensed to multiple partners to commercialize in the U.S. and ex-U.S. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.